BIVI · Biovie Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These circumstances raise substantial doubt on the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-K filed Aug 13, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score Cluster buy
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-28 | Chappell Amy Suzon |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock were purchased by the Reporting Person in an open market transaction. |
Common Stock
|
727 |
| 2026-08-28 | Palumbo Joseph M |
Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock were purchased in several open market transactions, all at the same price. The reported price does not reflect a weighted average price. |
Common Stock
|
4,843 |
| 2026-08-28 | KIM JOANNE WENDY |
Chief Financial Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock were purchased by the Reporting Person in an open market transaction. |
Common Stock
|
2,500 |
| 2026-08-27 | DO CUONG V |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price at which shares were purchased in several open market transactions on August 27, 2026, at prices ranging from $2.05 to $2.10, inclusive. The reporting person undertakes to provide BioVie Inc., any stockholder of BioVie Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
15,210 |
| 2026-01-05 | KIM JOANNE WENDY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. |
Stock Option (right to buy)
|
110,100 |
| 2026-01-05 | Lang James Paul |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. |
Stock Option (right to buy)
|
90,000 |
| 2026-01-05 | Lang James Paul |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. |
Stock Option (right to buy)
|
330,500 |
| 2026-01-05 | Chappell Amy Suzon |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
7,500 shares underlying the options vest on grant date and the remaining balance will vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. |
Stock Option (right to buy)
|
57,500 |
| 2026-01-05 | Sherman Michael Edward |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. |
Stock Option (right to buy)
|
341,100 |
| 2026-01-05 | ROGICH SIGMUND |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. |
Stock Option (right to buy)
|
141,100 |
| 2026-01-05 | ROGICH SIGMUND |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. |
Stock Option (right to buy)
|
70,000 |
| 2026-01-05 | DO CUONG V |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Indirect)
55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Securities are held in the name of Do & Rickles Investments LLC. |
Stock Option (right to buy)
(I)
|
665,300 |
| 2026-01-05 | Farag Kameel D. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
7,500 shares of the underlying options vest s on grant date and the remaining balance in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. |
Stock Option (right to buy)
|
57,500 |
| 2026-01-05 | Palumbo Joseph M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029 |
Stock Option (right to buy)
|
132,000 |
| 2026-01-05 | Sherman Michael Edward |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. |
Stock Option (right to buy)
|
80,000 |
| 2025-08-07 | DO CUONG V |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $2.00 in connection with the issuer's public offering that closed on August 11, 2025. Securities are held in the name of Do & Rickles Investments LLC. |
Common Stock
(I)
|
5,000 |
| 2025-08-07 | DO CUONG V |
Director |
Buy↑
Filing footnotes — Warrants (right to buy) (Indirect)
The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $2.00 in connection with the issuer's public offering that closed on August 11, 2025. Securities are held in the name of Do & Rickles Investments LLC. |
Warrants (right to buy)
(I)
|
5,000 |
| 2024-12-20 | BERMAN RICHARD J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
23,155 |
| 2024-12-20 | ROGICH SIGMUND |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
22,070 |
| 2024-12-20 | DO CUONG V |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Indirect)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. Securities are held in the name of Do & Rickles Investments LLC. |
Stock Option (right to buy)
(I)
|
104,502 |
| 2024-12-20 | Lang James Paul |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
22,690 |
| 2024-12-20 | Sherman Michael Edward |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
23,325 |
| 2024-12-20 | Palumbo Joseph M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
15,417 |
| 2024-12-20 | KIM JOANNE WENDY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
14,417 |
| 2024-12-20 | Hariri Robert J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Stock Option (right to buy)
|
21,815 |
| 2024-11-20 | ROGICH SIGMUND |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
Common Stock
|
32,700 |
| 2024-11-20 | Sherman Michael Edward |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
Stock Option (right to buy)
|
56,900 |
| 2024-11-20 | Lang James Paul |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
Stock Option (right to buy)
|
61,600 |
| 2024-11-20 | BERMAN RICHARD J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
Common Stock
|
34,200 |
| 2024-11-20 | Hariri Robert J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
Stock Option (right to buy)
|
49,800 |
| 2024-06-24 | Palumbo Joseph M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal annual installments beginning on June 24, 2024. |
Stock Option (right to buy)
|
156,000 |
| 2024-06-24 | DO CUONG V |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Indirect)
The options vest in three equal annual installments beginning on June 24, 2024. Securities are held in the name of Do & Rickles Investments LLC. |
Stock Option (right to buy)
(I)
|
227,000 |
| 2024-06-24 | DO CUONG V |
Director |
Award↑
Filing footnotes — Common Stock (Indirect)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. Securities are held in the name of Do & Rickles Investments LLC. |
Common Stock
(I)
|
168,000 |
| 2024-06-24 | Palumbo Joseph M |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. |
Common Stock
|
116,000 |
| 2024-06-24 | KIM JOANNE WENDY |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. |
Common Stock
|
18,250 |
| 2024-06-24 | Palumbo Joseph M |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. |
Common Stock
|
29,000 |
| 2024-06-24 | KIM JOANNE WENDY |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. |
Common Stock
|
73,000 |
| 2024-06-24 | KIM JOANNE WENDY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in three equal annual installments beginning on June 24, 2024. |
Stock Option (right to buy)
|
99,000 |
| 2024-06-24 | DO CUONG V |
Director |
Tax↓
Filing footnotes — Common Stock (Indirect)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. Securities are held in the name of Do & Rickles Investments LLC. |
Common Stock
(I)
|
42,000 |
| 2024-03-04 | DO CUONG V |
Director |
Buy↑
Filing footnotes — Common stock (Indirect)
The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $1.00 in connection with the issuer's public offering that closed on March 6, 2024. Securities are held in the name of Do & Rickles Investments LLC. |
Common stock
(I)
|
10,000 |
| 2024-03-04 | DO CUONG V |
Director |
Buy↑
Filing footnotes — Warrants (right to buy) (Indirect)
The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $1.00 in connection with the issuer's public offering that closed on March 6, 2024. Securities are held in the name of Do & Rickles Investments LLC. |
Warrants (right to buy)
(I)
|
5,000 |
| 2024-02-15 | DO CUONG V |
Director |
Tax↓
Filing footnotes — Common Stock (Indirect)
Securities are held in the name of Do & Rickles Investments LLC. |
Common Stock
(I)
|
4,953 |
| 2024-02-15 | Palumbo Joseph M |
Chief Medical Officer |
Tax↓
|
Common Stock
|
2,476 |
| 2024-02-15 | KIM JOANNE WENDY |
Chief Financial Officer |
Tax↓
|
Common Stock
|
2,476 |
| 2023-12-11 | KIM JOANNE WENDY |
Chief Financial Officer |
Award↑
|
Common Stock
|
5,000 |
| 2023-12-01 | GORLIN STEVE |
Director |
Sell↓
|
Common Stock
|
75,680 |
| 2023-11-30 | DO CUONG V |
Director |
Buy↑
|
Common stock
|
10,000 |
| 2023-11-09 | Lang James Paul |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest in four equal installments beginning on February 9, 2024, with the remaining installments vesting on May 9, 2024, August 9, 2024 and the earlier of November 9, 2024 or the date of the issuer's 2024 annual shareholders' meeting. |
Stock Option (right to buy)
|
93,500 |
| 2023-11-09 | Hariri Robert J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on September 22, 2023, subject to board approval, which was obtained on November 9, 2023. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments beginning on February 9, 2024, with the remaining installments vesting on May 9, 2024, August 9, 2024 and the earlier of November 9, 2024 or the date of the issuer's 2024 annual shareholders' meeting. |
Common Stock
|
42,254 |
| 2023-11-09 | GORLIN STEVE |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on September 22, 2023, subject to board approval, which was obtained on November 9, 2023. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments beginning on February 9, 2024, with the remaining installments vesting on May 9, 2024, August 9, 2024 and the earlier of November 9, 2024 or the date of the issuer's 2024 annual shareholders' meeting. |
Common Stock
|
46,358 |